The MIST Clinical Study for PPF

Trial Objectives

Progressive Pulmonary Fibrosis, or PPF, is a rare lung disease that causes scarring in the lung over time. This causes difficulty breathing and worsened symptoms over time, including cough, fatigue or shortness of breath. Current treatments for PPF are in pill form. While they can slow the disease in some people, the high doses needed can cause side effects. Researchers in the MIST study want to know if the investigational study medication, an inhaled form of pirfenidone called AP01, can improve lung function and have fewer side effects.

Volunteers will be randomly assigned to receive oral pirfenidone or a placebo (a medication containing no active ingredient). At clinic visits, volunteers will receive physical examinations, have their lung function evaluated, and will receive questionnaires about their symptoms in the clinic and at home.